CLOSE
iStock
iStock

Attention Knitters: Oklahoma Needs 5000 Baby Hats

iStock
iStock

In what must be some kind of record for soliciting infant head cozies, the Oklahoma State Department of Health (OSDH) has put out an open call for hand-knitted baby hats. And not just any baby hats—they have to be purple.

The campaign is part of an effort to raise awareness of Shaken Baby Syndrome, a form of abusive head trauma that's a damaging parental response to excessive crying and can result in serious brain injury. The effort, dubbed "Click for Babies" after the sound knitting needles make, is intended to highlight the potential hazards of improper infant care.

Why purple? Because the National Center for Shaken Baby Syndrome refers to an infant’s period of prolonged crying as the PURPLE period. The word is an acronym for reminders about the syndrome: L, for example, stands for Long-Lasting. Babies can cry for five hours a day, up to four months of age.

Potential donors should choose a washable, soft yarn, with the hat standing 4 to 6 inches high. Due to potential choking hazards, decorations are not recommended.

OSDH will be collecting caps through October 1 and the knitwear will be distributed to birthing hospitals and public health facilities along with a booklet on Shaken Baby Syndrome. If you’d like to donate a hat, you can mail it to any one of three addresses listed on the state’s web site. The program is hoping to receive 5000 hats for the cause. You can also check out the Click for Babies website to see if the campaign is being promoted in your state.

[h/t ABC News]

nextArticle.image_alt|e
iStock
arrow
Medicine
New Cancer-Fighting Nanobots Can Track Down Tumors and Cut Off Their Blood Supply
iStock
iStock

Scientists have developed a new way to cut off the blood flow to cancerous tumors, causing them to eventually shrivel up and die. As Business Insider reports, the new treatment uses a design inspired by origami to infiltrate crucial blood vessels while leaving the rest of the body unharmed.

A team of molecular chemists from Arizona State University and the Chinese Academy of Sciences describe their method in the journal Nature Biotechnology. First, they constructed robots that are 1000 times smaller than a human hair from strands of DNA. These tiny devices contain enzymes called thrombin that encourage blood clotting, and they're rolled up tightly enough to keep the substance contained.

Next, researchers injected the robots into the bloodstreams of mice and small pigs sick with different types of cancer. The DNA sought the tumor in the body while leaving healthy cells alone. The robot knew when it reached the tumor and responded by unfurling and releasing the thrombin into the blood vessel that fed it. A clot started to form, eventually blocking off the tumor's blood supply and causing the cancerous tissues to die.

The treatment has been tested on dozen of animals with breast, lung, skin, and ovarian cancers. In mice, the average life expectancy doubled, and in three of the skin cancer cases tumors regressed completely.

Researchers are optimistic about the therapy's effectiveness on cancers throughout the body. There's not much variation between the blood vessels that supply tumors, whether they're in an ovary in or a prostate. So if triggering a blood clot causes one type of tumor to waste away, the same method holds promise for other cancers.

But before the scientists think too far ahead, they'll need to test the treatments on human patients. Nanobots have been an appealing cancer-fighting option to researchers for years. If effective, the machines can target cancer at the microscopic level without causing harm to healthy cells. But if something goes wrong, the bots could end up attacking the wrong tissue and leave the patient worse off. Study co-author Hao Yan believes this latest method may be the one that gets it right. He said in a statement, "I think we are much closer to real, practical medical applications of the technology."

[h/t Business Insider]

nextArticle.image_alt|e
iStock
arrow
Medicine
New Peanut Allergy Patch Could Be Coming to Pharmacies This Year
iStock
iStock

About 6 million people in the U.S. and Europe have severe peanut allergies, including more than 2 million children. Now, French biotechnology company DBV Technologies SA has secured an FDA review for its peanut allergy patch, Bloomberg reports.

If approved, the company aims to start selling the Viaskin patch to children afflicted with peanut allergies in the second half of 2018. The FDA's decision comes in spite of the patch's disappointing study results last year, which found the product to be less effective than DBV hoped (though it did receive high marks for safety). The FDA has also granted Viaskin breakthrough-therapy and fast-track designations, which means a faster review process.

DBV's potentially life-saving product is a small disc that is placed on the arm or between the shoulder blades. It works like a vaccine, exposing the wearer's immune system to micro-doses of peanut protein to increase tolerance. It's intended to reduce the chances of having a severe allergic reaction to accidental exposure.

The patch might have competition: Aimmune Therapeutics Inc., which specializes in food allergy treatments, and the drug company Regeneron Pharmaceuticals Inc. are working together to develop a cure for peanut allergies.

[h/t Bloomberg]

SECTIONS

arrow
LIVE SMARTER
More from mental floss studios